Skip to main content
NCBI home page
Pediatric Rheumatology logoLink to Pediatric Rheumatology
. 2021 Sep 16;19:145. doi: 10.1186/s12969-021-00611-4

Infections and antibiotics during fetal life and childhood and their relationship to juvenile idiopathic arthritis: a prospective cohort study

Erik Kindgren 1,2,✉, Johnny Ludvigsson 3
PMCID: PMC8447683  PMID: 34530851

Abstract

Background

The aetiology of juvenile idiopathic arthritis (JIA) is poorly understood. It has been shown that use of antibiotics is associated with JIA. However, whether the association is due to increased occurrence of infection in these individuals is unknown. The purpose of this investigation was to measure the association between number of infections and use of antibiotics during childhood with development of JIA.

Methods

In ABIS (All Babies in Southeast Sweden) a population-based prospective birth cohort of 17,055 children, data were collected on infections and antibiotic exposure during pregnancy and childhood. 102 individuals with JIA were identified. Multivariable logistic regression analyses were performed, adjusting for confounding factors.

Results

Exposure to antibiotics during the periods 1–12 months, 1–3 years and 5–8 years was significantly associated with increased risk for JIA. The odds of developing JIA were three times higher in those exposed to antibiotics during the first 3 years of life compared with those not exposed (aOR 3.17; 95% CI 1.11–9.03, p = 0.031), and more than twice as high in those exposed to antibiotics during the first 5 years of life compared with those not exposed (aOR 2.18; 95% CI 1.36–3.50, p = 0.001). The odds of developing JIA were 78% higher in those exposed to antibiotics during the first 8 years of life compared with those not exposed (aOR 1.78; 95% CI 1.15–2.73, p = 0.009). Occurrence of infection during fetal life or childhood showed no significant association with the risk of developing JIA, after confounder adjustment.

The cumulative number of courses of antibiotics was significantly higher during childhood for the individuals who developed JIA (p < 0.001). Penicillins were more frequently used than non-penicillins, but both had an equal effect on the risk of developing JIA.

Conclusions

Exposure to antibiotics early in life is associated with later onset of JIA in a large birth cohort from the general population. The relationship was dose dependent. These results suggest that further, more restrictive, antibiotic policies during the first years of life would be advisable.

Keywords: Juvenile idiopathic arthritis (JIA), Antibiotics, Infections, Arthritis, Epidemiology, Autoimmunity, Rheumatic disease

Background

The incidence of autoimmune diseases has increased over the last 50 years in parallel with an increased standard of living [1]. The underlying causes of JIA are mostly unknown [2]. Most rheumatic diseases are characterized by joint inflammation; however, inflammation can develop elsewhere in the body several years before the onset of joint inflammation [3–5]. Both juvenile idiopathic arthritis (JIA) and rheumatoid arthritis (RA) are commonly referred to as autoimmune diseases. Genetic components make up only a small part (10–25%) of the cause, and unknown environmental factors are believed to be the main cause of the disease [6, 7]. Environmental factors such as viral infections have been suggested, but other studies have not been able to confirm these results [8–13].

The intestinal microbiota is an environmental factor that affects metabolic and immunological homeostasis, maintains the integrity of the intestinal mucosa, and trains and contributes to the maturation of the immune system [14–17]. In a paediatric population whose immune system has not fully matured, changes in the intestinal microbiota may be more decisive for development of immune-mediated diseases than in adults. Thus, events in early life such as delivery method, diet, infections, and exposure to antibiotics may have a pronounced impact on the risk of developing autoimmune diseases in children. There is a great body of data indicating that antibiotic use, especially during childhood, is an important risk factor for development of atopy and inflammatory bowel disease [18]. Antibiotics are one of the most common prescription drugs in children and it seems to disrupt with the normal maturation of the microbiome [19–21]. A recent systematic review has compiled evidence that antibiotic exposure in children is associated with a reduction in wealth and / or diversity and a change in the balance between species in the microbiome with reductions in the number of commensal bacteria that are considered beneficial [22],

It has been shown that use of antibiotics is associated with both JIA and RA [23–25]. However, the association of is due to an increased number of infections, rather than use of the antibiotic, is unknown. In a large national register study with a case-control approach, it was noted that hospital care for infection in the first year of life was almost twice as common among those who later developed JIA [26]. A Finnish population study suggested that repeated childhood antibiotic exposure was associated with a subsequent diagnosis of JIA, but the study could not differentiate the effects of antibiotic use from the effects of infection [23]. Another study showed that antibiotics were associated with newly diagnosed JIA in a dose- and time-dependent manner in a paediatric population [24]. None of these studies had the opportunity to perform subgroup analyses for each JIA category to determine whether antibiotics were only associated with specific JIA manifestations.

To further elucidate the role of infections and/or use of antibiotics, the purpose of this study was to investigate the association between occurrence of infections and use of antibiotics during fetal life and childhood with later development of JIA.

Methods

All parents of children born from October 1, 1997 to October 1, 1999 in south-eastern Sweden were asked to participate in ABIS (All Babies in South-east Sweden) [27, 28]. Of the 21,700 families surveyed, 17,055 (78.6%) participated. Blood samples have been taken from the children at birth (umbilical cord blood) and then at 1, 3, 5, and 8 years. Parental questionnaires containing information on nutrition, infections, drug use, vaccinations, and other factors were answered at birth, then at recurring intervals during childhood (including at 1, 3, 5 and 8 years of age). A primary purpose of the ABIS cohort is to identify the importance of environmental factors for development of immune-mediated diseases and elucidate how these genetic and environmental factors interact [27].

To increase likelihood of detection for all patients with JIA, three methods were used to identify the patients. First, the parents indicated on a questionnaire at each follow-up whether the child was diagnosed with JIA. Second, data from the ABIS cohort was linked to the Swedish national patient register (https://www.socialstyrelsen.se/en/statistics-and-data/registers/register-information/the-national-patient-register/) with the help of the Swedish social security number, a unique 10-digit code [29]. Third, the diagnosis was validated upon review of the medical records for the patients, which resulted in some exclusions due to misdiagnosis (mostly monoarthritis, which later manifested as reactive arthritis). We identified 102 children with an International Classification of Diseases (ICD) code for JIA (ICD 9–10 code M08–M09) and who had agreed to participate in ABIS (see Fig. 1). Finally, all cases of JIA and their categories were cross-referenced via the Swedish JIA register (http://www.barnreumaregistret.se/), in which all pediatric rheumatologists in Sweden register and follow up their patients.

Fig. 1.

Fig. 1

Open in a new tab

Flow-chart of the study sample, showing the number of total participants, patients with Juvenile Idiopathic Arthritis (JIA). ICD, International Classification of Diseases

Exposure to infections and antibiotics was analysed from the questionnaires at birth, 1, 3, 5, and 8 years of age. At all age ranges, the questionnaire elicited the frequency of infections (otitis, tonsillitis, upper respiratory tract infection, pneumonia, meningitis, gastroenteritis, three-day fever, and influenza), as well as whether the child had experienced any infection that required antibiotic treatment. From the age of 3 years, the questionnaire also asked whether the child had been exposed to penicillin or other antibiotics (in this article referred to as non-penicillins).

Penicillin was explained in the questionnaires as a trademark for amoxicillin, phenoxymethylpenicillin, amoxicillin/clavulanic acid, while other antibiotics were explained as trademarks for trimethoprim, sulfamethoxazole, erythromycin, loracarbef, clarithromycin, cefadroxil, cefuroxime, clindamycin, among others.

Statistical analysis

Multiple logistic regression was used to estimate the odds ratio (OR), with a 95% CI, for the significance of the explanatory variable. A p-value below 0.05 and a 95% CI not overlapping the null value 1.00 for the OR was regarded as statistically significant.

We adjusted our estimates for a wide range of confounding factors in a multiple regression model, generating an adjusted odds ratio (aOR). To investigate whether it is the underlying infection or course of antibiotics that is associated with JIA, these variables were adjusted against each other. Similarly, both infections and exposure to antibiotics were adjusted against breastfeeding, gestational age, and parental level of education in the final multiple regression model. Chi-square tests were used to assess the relationship between variables in basic characteristics. Statistical testing was corrected for false discovery rate (FDR) using the Benjamini & Hochberg method.

Statistics were calculated using IBM SPSS Statistics for Windows, version 25 (IBM Corp., Armonk, NY, USA).

Results

A total of 17,055 children were included in the study, 102 of whom later received a JIA diagnosis during the follow-up period, which was 19 years. The median age at diagnosis was 12.0 years (1.9–16.0). Most cases were female (68%). The most common JIA category was oligoarthritis, followed by polyarthritis. The baseline characteristics of the study population are summarized in Table 1.

Table 1.

Basic characteristics of cases and controls

Controls JIA
n (%) n (%) p
No. of subjects 16,369 102
Sex
 Boys 8453 (52%) 33 (32%) < 0.001
 Girls 7814 (48%) 69 (68%)
Gestational age, weeks (SD) 39.7 (2.4) 39.6 (2.0) 0.511
Season of birth
 Winter (December–February) 3840 (24%) 18 (18%) 0.155
 Spring (March–May) 4607 (28%) 34 (33%) 0.268
 Summer (June–August) 4270 (26%) 26 (25%) 0.854
 Autumn (September–November) 3523 (22%) 24 (24%) 0.654
Category at Onset (ILAR) (n)
 Systemic Arthritis 7 (7%)
 Oligoarthritis 25 (25%)
  Persistent oligoarthritis 19 (19%)
  Extended oligoarthritis 6 (6%)
 Polyarthritis (Rheumatoid Factor Negative) 16 (16%)
 Polyarthritis (Rheumatoid Factor Positive) 4 (4%)
 Psoriatic Arthritis 11 (11%)
 Enthesitis Related Arthritis 16 (16%)
 Undifferentiated Arthritis 23 (23%)
Open in a new tab

JIA = juvenile idiopathic arthritis; ILAR = International League of Associations for Rheumatology

P-value from chi-square test. Bold shows results reaching statistical significance (p-value below 0.05)

Infections, mainly reflecting bacterial infections, such as otitis during the first year of life was more frequent among cases than controls (39% vs 26%), as was tonsillitis in children aged 5–8 years (28% vs 15%), but after adjustment for potential confounders, including antibiotic treatment, the association no longer held significance. Other infections, mainly reflecting probable virus infections (upper respiratory tract infection, pneumonia, meningitis, gastroenteritis, three-day fever, and influenza) showed no statistical differences between cases and controls (Table 2).

Table 2.

Number of infections during childhood in those who later developed JIA and in controls from the general population

Control JIA aOR (95% CI) p
From 1 to 12 month
 Upper respiratory tract infection (mean; SD) 3.7 (2.2) 3.9 (2.2) OR 0.9 (0.6–1.2) .382
 Gastroenteritis 0.5 (0.8) 0.6 (0.8) OR 1.5 (0.6–3.6) .345
 Influenza 0.2 (0.6) 0.3 (0.7) OR 1.0 (1.0–1.0) .995
From 1 to 3 years
 Common cold 5.3 (2.3) 5.5 (2.3) OR 1.0 (0.8–1.4) .810
 Tonsillitis 0.3 (0.8) 0.3 (0.6) OR 1.0 (1.0–1.0) .994
 Otitis 1.3 (1.8) 1.6 (1.9) OR 1.3 (0.8–1.9) .261
 Pneumonia 0.1 (0.4) 0.2 (0.5) OR 1.3 (0.3–6.0) .764
 Meningitis 0.0 (0.1) 0.0 (0.0) OR 1.0 (1.0–1.0) .999
 Gastroenteritis 1.4 (1.3) 1.2 (1.0) OR 0.5 (0.2–1.1) .074
 Three-day fever 0.6 (1.0) 0.6 (0.7) OR 0.9 (0.4–1.9) .845
 Influenza 0.8 (1.2) 0.4 (0.8) OR 0.6 (0.2–1.6) .297
From 3 to 5 years
 Common cold 5.7 (2.3) 5.8 (2.1) OR 1.0 (0.7–1.3) .894
 Tonsillitis 0.5 (1.1) 0.8 (1.5) OR 0.9 (0.4–1.9) .837
 Otitis 1.2 (1.7) 1.3 (2.0) OR 0.7 (0.4–1.4) .331
 Pneumonia 0.1 (0.3) 0.1 (0.4) OR 2.2 (0.5–10.4) .323
 Meningitis 0.0 (0.2) 0.0 (0.0) OR 1.0 (1.0–1.0) .999
 Gastroenteritis (viral) 2.1 (1.5) 2.4 (1.8) OR 1.1 (0.7–1.7) .556
 Gastroenteritis (bacterial) 0.1 (0.4) 0.1 (0.3) OR 1.0 (1.0–1.0) .997
 Pneumonia 0.1 (0.4) 0.1 (0.5) OR 1.3 (0.3–6.5) .748
 Three-day fever 0.5 (1.0) 0.6 (1.4) OR 1.1 (0.5–2.9) .774
 Influenza 0.9 (1.3) 1.3 (1.5) OR 1.1 (0.6–2.2) .693
From 5 to 8 years
 Common cold 4.0 (2.1) 4.6 (2.3) OR 1.2 (0.9–1.7) .252
 Tonsillitis 0.3 (0.8) 0.5 (0.9) OR 1.1 (0.4–2.6) .899
 Otitis 0.5 (1.1) 0.7 (1.4) OR 1.0 (1.0–1.0) .992
 Meningitis 0.0 (0.2) 0.0 (0.0) OR 1.0 (1.0–1.0) .999
 Gastroenteritis 1.4 (1.3) 1.7 (1.2) OR 1.5 (0.8–2.5) .181
 Influenza 0.7 (1.0) 0.9 (1.1) OR 1.0 (0.5–2.0) .937
Open in a new tab

JIA = juvenile idiopathic arthritis; aOR = adjusted odds ratio (from logistic regression)

Exposure to antibiotics during the periods 1–12 months, 1–3 years and 5–8 years was significantly associated with a risk of JIA, when all JIA categories were analysed together (Table 3). The cumulative number of courses of antibiotics was also significantly higher during the first 8 years of life for the individuals who developed JIA (Fig. 2). Penicillins were used more frequently than non-penicillins, but both types of antibiotics had an equal effect on the risk of developing JIA (Table 3).

Table 3.

Exposure to antibiotics in the uterus and during the early childhood of those children who later developed JIA, compared to controls from the general population

graphic file with name 12969_2021_611_Tab3_HTML.jpg

Open in a new tab

The adjusted odds ratio is calculated in the logistic regression. Bold shows results reaching statistical significance (p-value below 0.05 and 95% CI not overlapping the null value of 1.00).

Fig. 2.

Fig. 2

Open in a new tab

Number of doses of antibiotics (per time period) during childhood and cumulative number of antibiotic doses in children who later developed JIA, compared to controls from the general population

The odds of developing JIA were three times higher in those who had been exposed to antibiotics during the first 3 years of life compared with those who had not (aOR 3.17; 95% CI 1.11–9.03, p = 0.031). The corresponding odds of developing JIA were more than twice as high in those who had been exposed to antibiotics during the first 5 years of life compared with those who had not been exposed (aOR 2.18; 95% CI 1.36–3.50, p = 0.001). In addition, the odds of developing JIA were 78% higher in those who had been exposed to antibiotics during the first 8 years of life compared with those who had not been exposed (aOR 1.78; 95% CI 1.15–2.73, p = 0.009).

Since systemic-onset JIA (sJIA) is considered an autoinflammatory disease, it can be argued that this disease should not be assessed together with autoimmune diseases. All analyses in Table 3 were performed with sJIA (n = 7) excluded from the whole JIA group, and this did not change the result.

Categories of JIA and antibiotic consumption

All categories of JIA and their relationship to antibiotic consumption during childhood are presented in Table 4. sJIA was the only category of JIA that had significantly higher antibiotic use during pregnancy (aOR 5.26; 95% CI 1.18–23.51, p = 0.030). Oligoarticular JIA showed significantly higher use of number of doses of penicillins at 5–8 years of age (aOR 1.44; 95% CI 1.03–2.02, p = 0.034).

Table 4.

Exposure to antibiotics in the uterus and during the growth of those children who later developed JIA, categories of JIA compared to controls from the general population

JIA
Control sJIA aOR (95% CI) p Oligo aOR (95% CI) p Poly RF- aOR (95% CI) p Poly RF+ aOR (95% CI) p PsA aOR (95% CI) p ERA aOR (95% CI) p Undiff. aOR (95% CI) p
No. of subjects 16,489 7 25 16 4 11 16 23
During pregnancy
 Any antibiotics (Yes or No), n (%) 2997 (20%) 4 (57%) 5.3 (1.2–23.5) .030 7 (30%) 1.7 (0.7–4.2) .229 4 (27%) 1.4 (0.5–4.5) .537 0 (0%) NA# .986 1 (13%) 0.6 (0.1–4.6) .592 4 (25%) 1.3 (0.4–4.1) .636 1 (5%) 0.2 (0.0–1.6) .126
From birth to 1 month
 Any antibiotics (Yes or No), n (%) 644 (6%) 1 (20%) 3.8 (0.4–34.0) .233 2 (13%) 2.3 (0.5–10.4) .265 2 (14%) 2.5 (0.6–11.3) .225 0 (0%) NA# .993 0 (0%) NA# .993 1 (9%) 1.5 (0.2–11.9) .691 1 (7%) 1.1 (0.1–8.3) .937
From 1 to 12 month
 Infection with antibiotics (Yes or No), n (%) 3600 (38%) 3 (50%) 1.1 (0.6–2.3) .699 3 (23%) 0.8 (0.4–1.3) .345 8 (62%) 1.5 (1.0–2.4) .073 1 (50%) 1.1 (0.3–3.9) .823 2 (25%) 1.0 (0.6–1.9) .902 6 (67%) 1.9 (1.1–3.3) .029 6 (50%) 1.4 (0.9–2.2) .187
 No. of courses (any antibiotic), mean (SD) 0.7 (1.2) 0.8 (0.8) 1.0 (0.5–1.9) .996 0.5 (1.2) 0.8 (0.5–1.5) .533 1.3 (1.4) 1.3 (1.0–1.7) .101 0.8 (1.1) 1.0 (0.3–3.1) .998 1.5 (3.0) 1.3 (1.0–1.9) .088 1.8 (1.8) 1.4 (1.1–1.9) .011 1.5 (2.4) 1.3 (1.0–1.8) .037
From 1 to 3 years
 Infection with antibiotics (Yes or No), n (%) 4826 (60%) 4 (67%) 1.3 (0.2–7.3) .737 6 (75%) 2.0 (0.4–10.0) .394 8 (89%) 5.4 (0.7–42.8) .076 2 (67%) 1.5 (0.6–3.8) .426 3 (75%) 2.0 (0.2–19.3) .546 5 (83%) 3.3 (0.4–28.6) .270 8 (89%) 1.7 (1.0–3.0) .061
 Penicillin (Yes or No), n (%) 5352 (63%) 4 (67%) 1.2 (0.2–6.5) .840 7 (78%) 2.1 (0.4–10.0) .360 7 (70%) 1.4 (0.4–5.4) .634 2 (67%) 1.2 (0.1–13.1) .887 3 (75%) 1.8 (0.2–17.2) .615 6 (86%) 3.6 (0.4–29.7) .239 8 (89%) 4.8 (0.6–38.1) .141
 Non-penicillin (Yes or No), n (%) 1029 (13%) 1 (17%) 1.4 (0.2–11.9) .765 2 (25%) 2.3 (0.5–11.5) .305 3 (38%) 4.2 (1.0–17.4) .034 0 (0%) NA# .991 1 (33%) 3.5 (0.3–38.3) .310 2 (29%) 2.8 (0.5–14.3) .223 1 (14%) 1.2 (0.1–9.6) .894
 No. of courses (any antibiotic), mean (SD) 1.5 (1.9) 1.0 (0.8) 0.8 (0.5–1.5) .512 1.8 (1.5) 1.1 (0.8–1.5) .703 2.2 (1.5) 1.2 (0.9–1.5) .287 3.2 (4.3) 1.3 (0.9–2.0) .145 1.8 (1.7) 1.1 (0.7–1.7) .788 1.3 (0.6) 0.9 (0.6–1.5) .742 2.6 (2.4) 1.2 (1.0–1.6) .082
 No. of courses (penicillin), mean (SD) 1.5 (1.8) 1.8 (0.8) 1.0 (0.4–2.8) .987 2.0 (1.6) 1.5 (0.7–3.2) .281 1.9 (0.7) 1.1 (0.5–2.4) .771 1.8 (2.0) 1.3 (0.3–5.0) .704 2.0 (0.8) 1.3 (0.4–4.2) .661 2.6 (2.7) 1.3 (0.9–1.7) .115 2.3 (2.4) 1.7 (0.8–3.6) .135
 No. of courses (non-penicillin), mean (SD) 0.3 (0.9) 0.5 (1.2) 1.3 (0.8–2.1) .271 0.4 (0.7) 1.3 (0.7–2.7) .407 0.9 (1.2) 1.8 (1.0–3.2) .036 0.0 (0.0) NA# .991 0.7 (1.2) 1.6 (0.6–4.4) .387 0.8 (1.5) 1.6 (0.9–3.1) .141 0.2 (0.6) 1.0 (0.4–2.7) .974
From 3 to 5 years
 Infection with antibiotics (Yes or No), n (%) 4223 (61%) 2 (40%) 0.7 (0.4–1.6) .436 5 (45%) 0.8 (0.5–1.4) .495 6 (75%) 1.1 (0.6–2.0) .670 2 (100%) NA# .320 3 (60%) 1.1 (0.5–2.3) .770 2 (33%) 0.6 (0.3–1.2) .149 8 (67%) 1.1 (0.7–1.7) .684
 Penicillin (Yes or No), n (%) 4813 (67%) 5 (83%) 2.4 (0.3–20.9) .416 8 (67%) 1.0 (0.3–3.2) .967 5 (63%) 0.8 (0.2–3.4) .776 2 (100%) NA# .320 3 (60%) 0.7 (0.1–4.4) .732 2 (33%) 0.2 (0.0–1.3) .103 8 (73%) 1.3 (0.3–4.9) .699
 Non-penicillin (Yes or No), n (%) 837 (12%) 1 (17%) 1.5 (0.2–12.4) .735 2 (18%) 1.6 (0.3–7.5) .542 1 (13%) 1.0 (0.1–8.4) .974 0 (0%) NA# .992 1 (20%) 1.8 (0.2–16.2) .595 0 (0%) NA# .992 1 (11%) 0.9 (0.1–7.3) .926
 No. of courses (any antibiotic), mean (SD) 1.5 (1.8) 1.1 (1.7) 0.9 (0.5–1.6) .617 1.5 (2.5) 1.0 (0.7–1.4) .982 1.4 (1.2) 1.0 (0.7–1.4) .908 4.8 (4.6) 1.6 (1.0–2.5) .048 1.9 (2.0) 1.1 (0.7–1.7) .639 0.5 (0.8) 0.5 (0.2–1.3) .175 1.8 (2.3) 1.1 (0.8–1.4) .656
 No. of courses (penicillin), mean (SD) 1.7 (1.8) 2.2 (1.2) 1.5 (0.7–3.2) .243 1.8 (1.7) 1.1 (0.7–1.7) .809 1.4 (1.2) 0.9 (0.5–1.4) .528 4.8 (4.6) 1.6 (1.0–2.5) .048 1.4 (1.3) 0.9 (0.5–1.6) .750 1.6 (3.2) 0.7 (0.3–1.3) .250 1.3 (1.1) 1.0 (0.6–1.6) .919
 No. of courses (non-penicillin), mean (SD) 0.2 (0.8) 0.3 (0.8) 1.1 (0.4–3.0) .812 0.3 (0.6) 1.2 (0.6–2.4) .647 0.3 (0.7) 1.0 (0.4–2.6) .960 0.0 (0.0) NA# .992 0.4 (0.9) 1.2 (0.5–3.4) .675 0.0 (0.0) NA# .991 0.9 (2.7) 1.5 (1.0–2.0) .025
From 5 to 8 years
 Infection with antibiotics (Yes or No), n (%) 1450 (38%) 3 (75%) 1.9 (0.8–4.4) .120 5 (56%) 1.4 (0.8–2.5) .187 3 (50%) 1.4 (0.7–2.8) .281 0 (0%) NA NA 3 (100%) NA# .028 2 (40%) 1.5 (0.7–3.1) .267 1 (17%) 0.6 (0.2–1.6) .289
 Penicillin (Yes or No), n (%) 1562 (40%) 3 (75%) 4.5 (0.5–43.5) .192 4 (44%) 1.2 (0.3–4.5) .781 3 (50%) 1.5 (0.3–7.5) .616 0 (0%) NA NA 3 (100%) NA# .034 2 (40%) 1.0 (0.2–6.0) .996 2 (33%) 0.8 (0.1–4.1) .744
 Non-penicillin (Yes or No), n (%) 237 (6%) 3 (0%) 0.0 (0.0–0.0) .996 16 (0%) 0.0 (0.0–0.0) .995 2 (33%) 7.6 (1.4–41.6) .006 0 (0%) NA NA 0 (0%) NA# .996 4 (100%) 5.1 (0.5–48.8) .161 0 (0%) NA# .995
 No. of courses (any antibiotic), mean (SD) 0.8 (1.3) 1.8 (1.7) 1.4 (0.9–2.1) .142 1.4 (1.6) 1.3 (0.9–1.8) .154 1.6 (2.0) 1.3 (0.9–1.9) .131 0 (0%) NA NA 1.5 (0.0) 1.3 (0.8–2.2) .334 2.4 (3.6) 1.5 (1.1–2.1) .011 0.3 (0.6) 0.5 (0.1–1.9) .309
 No. of courses (penicillin), mean (SD) 0.7 (1.1) 1.5 (1.0) 1.7 (0.7–4.2) .236 1.5 (1.9) 1.4 (1.0–2.0) .034 1.2 (1.3) 1.3 (0.8–2.1) .313 0 (0%) NA NA 2.0 (0.0) 2.7 (0.9–8.6) .091 2.4 (3.6) 1.7 (1.2–2.4) .002 0.5 (0.8) 0.8 (0.3–2.0) .613
 No. of courses (non-penicillin), mean (SD) 0.1 (0.5) 0.0 (0.0) NA# .995 0.0 (0.0) NA# .995 0.7 (1.0) 2.3 (1.1–4.8) .027 0 (0%) NA NA 0.0 (0.0) NA# .996 2.0 (4.0) 2.9 (1.3–6.2) .007 0.0 (0.0) NA# .995
Open in a new tab

The adjusted odds ratio is calculated in the logistic regression. Bold shows results reaching statistical significance (p-value below 0.05 and 95% CI not overlapping the null value of 1.00). NA = not applicable. # = p-value from Chi-square test

JIA = juvenile idiopathic arthritis; sJIA = systemic juvenile idiopathic arthritis; aOR = adjusted odds ratio; Oligo = oligoarticular arthritis; Poly RF- = polyarticular rheumatoid-factor-negative arthritis; Poly RF+ = polyarticular rheumatoid-factor-positive arthritis; PsA = psoriatic arthritis; ERA = enthesitis-related arthritis; Undiff. = undifferentiated arthritis

Those who fell ill with rheumatoid-factor-negative polyarthritis had a tendency toward higher antibiotic consumption during the first year of life (aOR 1.52; 95% CI 0.96–2.41, p = 0.073), significantly higher use of non-penicillins at the age of 1–3 years (aOR 1.83; 95% CI 1.04–3.21, p = 0.036) and 5–8 years (aOR 7.59; 95% CI 1.38–41.63, p = 0.006). Only four individuals had rheumatoid-factor-positive polyarthritis; despite this, a statistically significant increase in the intake of penicillins at 3–5 years of age (aOR 1.59; 95% CI 1.00–2.53, p = 0.049) was noted. Psoriatic arthritis showed a tendency toward an increase in antibiotic use in the first year of life and significantly higher use of penicillins at 5–8 years of age (p = 0.028).

Enthesitis-related arthritis showed a clear significant increase in the use of antibiotics, in the first year of life (aOR 1.87; 95% CI 1.06–3.28, p = 0.029) and at 5–8 years of age (aOR 1.52; 95% CI 1.10–2.09, p = 0.011), for both penicillin and non-penicillins. The group with undifferentiated arthritis, which either does not meet the criteria for any category or meets the criteria for several categories, showed significantly increased antibiotic use during the first year of life (aOR 1.34; 95% CI 1.02–1.77, p = 0.037) as well as for non-penicillins at 3–5 years of age (aOR 1.46; 95% CI 1.05–2.04, p = 0.025). In addition, there was a tendency for increased use of antibiotics at the age of 1–3 years (aOR 1.72; 95% CI 0.98–3.05, p = 0.061).

Discussion

The purpose of this study was to investigate the association between infections, antibiotics and JIA. By analyzing data from a prospective birth cohort, which reflects the general population, we have found clear associations between exposure to antibiotics early in life and later onset of JIA. Our findings suggest a causal link between antibiotics and the development of JIA, which supports the hypothesis that antibiotic-induced dysregulation of the microbiome may trigger or accelerate the development of the autoimmune disease JIA in genetically predisposed children. The odds of developing JIA were three times higher in those exposed to antibiotics during childhood, compared with those not exposed. Infections during childhood, when controlling for other factors, did not show any statistically significant association with the risk of JIA. With sJIA, which is the category of JIA that most often presents initially with fluctuating fever, it is conceivable that antibiotic use would be overrepresented, which might distort the results. However, no such increased use was observed from birth to the age of 8 years in this group, only increased exposure to antibiotics during pregnancy.

Otitis (during the first year of life) and tonsillitis (at 5–8 years), often regarded as bacterial and therefore treated with antibiotics, were found more frequently in the cases than the controls, but after adjustment for potential confounders, including antibiotic treatment, this connection disappeared. This further strengthens the theory that it is antibiotic treatment itself, and not the infection, that is the environmental factor that predisposes to JIA.

The results of this study, with a clear association between exposure to antibiotics and the risk of later developing JIA, harmonize with the results of Horton et al. and Arvonen et al. [23, 24]. The data support treating different categories of JIA as separate groups for study in a subgroup analysis [30, 31]. While previous studies have not had the opportunity to do this, our material (presented in Table 4) has made this possible.

Only one JIA category showed association with maternal exposure to antibiotics during pregnancy. Interestingly, it was sJIA, which is considered an autoinflammatory disease [32]. While there are very few children with sJIA in this study, the majority had mothers who were exposed to antibiotics compared with a fifth in the controls. The mechanism behind this could possibly be the gut microbiota as previous studies have shown that microbiome diversity was affected by maternal antibiotic usage [33], but also that composition of the intestinal microbiota is different in sJIA patients compared with healthy children [34].

It is possible that the frequent exposure to antibiotics may interfere with the normal intestinal microbiota and increase the permeability of the mucosa and consequently antigen leakage, ultimately contributing to the pathogenesis of arthritis [35, 36]. In addition, antibiotics appear to affect gene expression, protein activity, and overall metabolism of the microbiota, which may directly affect immune function [37], The human microbiome might play a significant role in development of autoimmunity, as the loss of immune tolerance can be caused by microbial composition changes [38, 39]. There are several hypotheses as to how microorganisms can elicit an immune response against the host if the tolerance mechanisms fail [40]. A growing number of studies revealing the incidence of intestinal dysbiosis in various autoimmune diseases, such as inflammatory bowel disease [41], type 1 diabetes mellitus [42] and systemic lupus erythematosus [43]. There is clear evidence that the intestinal mucosa has a functional abnormality in JIA. Among other things, increased leakage of the intestinal epithelial barrier has been described [35]. In addition, in JIA patients suffering from gastrointestinal symptoms, signs of altered mucosal immunity have been observed, such as inflammatory lesions in the intestine [44], ileal lymphonodular hyperplasia [45, 46], and expression of HLA-DR in abnormal sites of the intestinal mucosa [45].Enthesitis-related arthritis (ERA) has been associated with certain intestinal microbial populations in a case-control study [47]. But other categories of JIA have also shown indications of alterations in the microbiota, as described by Arvonen et al. [48]. The intestinal microbiota develops dramatically during the first years of life [49] and stabilizes at 2–3 years of age [50]. Antibiotic exposure has a strong and sustained effect on the developing and unstable intestinal system [51, 52]. In addition, antibiotic treatment for a week has been shown to interfere with the intestinal and urinary microbiota, with changes that are measurable up to one year after the end of treatment [53–55].

The relatively low number of cases is a weakness of this study. Dropouts due to loss to follow-up are significant, but these were not found to be associated with heredity or subsequent diagnosis; therefore, skewed attrition seems unlikely. Another limitation of the study is that an claims-based assessment of antibiotic prescriptions would have been preferable instead of parent registration. While data from the Swedish Prescribed Drug Register would enable a better delimitation of the type of antibiotic, the Swedish Prescribed Drug Register with personal identity numbers (that contains all prescribed drugs dispensed at pharmacies) was established first in July 2005 and was not available at the time of initial data collection.

Our study has several significant strengths. First, the prospective study design entails minimal risk of recall and selection biases, which may occur in retrospective studies. However, this is also true for the two previous studies concerning antibiotics and JIA, whether they are register studies or claim based [23, 24]. The prospective design distributes all possible measurement biases equally between JIA cases and non-cases. In addition, the ABIS cohort has proven to be representative of the Swedish population, including current level of education [56]. Second, all cases of JIA were collected via the unique ten-digit personal identity number and ICD codes from the Swedish patient register, which has more than 99% coverage of all visits to both private and public care providers. This is a significant advantage over studies that rely solely on self-reporting. Third, we have validated all diagnoses via the Swedish Pediatric Rheumatology Registry and via medical records held at local health clinics and hospitals. Fourth, the availability of detailed information on important factors in early life allowed us to check for several potential confounding factors that may have affected our observed associations. To clarify the causal relationship between antibiotic exposure and JIA, our future study is focused on the microbiota during childhood and prior to diagnosis.

Conclusions

In summary, this study shows that exposure to antibiotics early in life is associated with later onset of JIA in a large birth cohort from the general population. The relationship was dose dependent. Infections per se during childhood showed no significant association with the risk of developing JIA after adjusting for confounders. The findings suggest a causal relationship between use of antibiotics specifically and the development of JIA. Irrespective of mediating mechanisms, these results suggest that restrictive antibiotic policies during the first years of life should be advisable.

Acknowledgements

We thank all the children and their parents in the ABIS study and the staff who work with the collection of questionnaires and biological samples. We are also grateful to Angelica Ahrens for reviewing the final manuscript, and to the Board of registry of the Swedish paediatric JIA-registry.

Financial disclosure

The authors have no financial relationships relevant to this article to disclose.

Abbreviations

JIA

juvenile idiopathic arthritis

ABIS

All Babies in South-east Sweden

ICD

International Classification of Diseases

OR

odds ratio

aOR

adjusted odds ratio

CI

confidence interval

sJIA

systemic-onset juvenile idiopathic arthritis

ERA

enthesitis-related arthritis

Authors’ contributions

Dr. Kindgren was responsible for the collection of JIA patient data, statistical analyses, figures, data interpretation, and the writing of the manuscript. Professor Ludvigsson is the principal investigator in the ABIS study, constructed questionnaires, collected all data, and revised the paper. Both authors read and approved the final manuscript.

Funding

ABIS has been supported by, among others: Barndiabetesfonden (The Swedish Child Diabetes Foundation), Juvenile Diabetes Research Foundation, the Swedish Research Council. This project is also supported by the Research Fund at Skaraborgs Hospital, as well as Skaraborg Research and Development Council and the Skaraborg Institute for Research and Development. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Open Access funding provided by Linköping University.

Availability of data and materials

The datasets are available from Johnny Ludvigsson, project leader of ABIS, on reasonable request.

Declarations

Ethics approval and consent to participate

The ABIS study has ethical approval from the Research Ethics Committees of the Faculty of Health Science at Linköping University, Sweden, approval numbers 1997/96287 and 2003/03–092, and from the Medical Faculty of Lund University, Sweden (approval numbers 99227 and 99321). All parents of the children in the ABIS study gave their informed consent after receiving detailed oral and written information.

Consent for publication

None of the authors in this article report any conflict of interest or competing interests.

Competing interests

The authors have no competing interest to disclose.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Erik Kindgren, Email: erik@kindgren.org.

Johnny Ludvigsson, Email: johnny.ludvigsson@liu.se.

References

  • 1.Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med. 2002;347(12):911–920. doi: 10.1056/NEJMra020100. [DOI] [PubMed] [Google Scholar]
  • 2.Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–778. doi: 10.1016/S0140-6736(07)60363-8. [DOI] [PubMed] [Google Scholar]
  • 3.McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–2219. doi: 10.1056/NEJMra1004965. [DOI] [PubMed] [Google Scholar]
  • 4.Deane KD, El-Gabalawy H. Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. Nat Rev Rheumatol. 2014;10(4):212–228. doi: 10.1038/nrrheum.2014.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Demoruelle MK, Deane KD, Holers VM. When and where does inflammation begin in rheumatoid arthritis? Curr Opin Rheumatol. 2014;26(1):64–71. doi: 10.1097/BOR.0000000000000017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Prahalad S, Zeft AS, Pimentel R, Clifford B, McNally B, Mineau GP, Jorde LB, Bohnsack JF. Quantification of the familial contribution to juvenile idiopathic arthritis. Arthritis Rheum. 2010;62(8):2525–2529. doi: 10.1002/art.27516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Savolainen A, Saila H, Kotaniemi K, Kaipianen-Seppanen O, Leirisalo-Repo M, Aho K. Magnitude of the genetic component in juvenile idiopathic arthritis. Ann Rheum Dis. 2000;59(12):1001. doi: 10.1136/ard.59.12.1001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Massa M, Mazzoli F, Pignatti P, De Benedetti F, Passalia M, Viola S, Samodal R, La Cava A, Giannoni F, Ollier W, et al. Proinflammatory responses to self HLA epitopes are triggered by molecular mimicry to Epstein-Barr virus proteins in oligoarticular juvenile idiopathic arthritis. Arthritis Rheum. 2002;46(10):2721–2729. doi: 10.1002/art.10564. [DOI] [PubMed] [Google Scholar]
  • 9.Pritchard MH, Matthews N, Munro J. Antibodies to influenza a in a cluster of children with juvenile chronic arthritis. Br J Rheumatol. 1988;27(3):176–180. doi: 10.1093/rheumatology/27.3.176. [DOI] [PubMed] [Google Scholar]
  • 10.Feldman BM, Birdi N, Boone JE, Dent PB, Duffy CM, Ellsworth JE, Lang BA, Laxer RM, Lewkonia RM, Malleson PN, Oen KG, Paquin JD, Rosenberg AM, Schneider R, Silverman ED. Seasonal onset of systemic-onset juvenile rheumatoid arthritis. J Pediatr. 1996;129(4):513–518. doi: 10.1016/S0022-3476(96)70115-4. [DOI] [PubMed] [Google Scholar]
  • 11.Soderlund M, von Essen R, Haapasaari J, Kiistala U, Kiviluoto O, Hedman K. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet. 1997;349(9058):1063–1065. doi: 10.1016/S0140-6736(96)09110-6. [DOI] [PubMed] [Google Scholar]
  • 12.Tsai YT, Chiang BL, Kao YF, Hsieh KH. Detection of Epstein-Barr virus and cytomegalovirus genome in white blood cells from patients with juvenile rheumatoid arthritis and childhood systemic lupus erythematosus. Int Arch Allergy Immunol. 1995;106(3):235–240. doi: 10.1159/000236848. [DOI] [PubMed] [Google Scholar]
  • 13.Weissbrich B, Suss-Frohlich Y, Girschick HJ. Seroprevalence of parvovirus B19 IgG in children affected by juvenile idiopathic arthritis. Arthritis Res Ther. 2007;9(4):R82. doi: 10.1186/ar2281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. Cell. 2012;148(6):1258–1270. doi: 10.1016/j.cell.2012.01.035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kamada N, Seo SU, Chen GY, Nunez G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol. 2013;13(5):321–335. doi: 10.1038/nri3430. [DOI] [PubMed] [Google Scholar]
  • 16.Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336(6086):1268–1273. doi: 10.1126/science.1223490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Brandtzaeg P. Homeostatic impact of indigenous microbiota and secretory immunity. Benefic Microbes. 2010;1(3):211–227. doi: 10.3920/BM2010.0009. [DOI] [PubMed] [Google Scholar]
  • 18.Verwoerd A, Ter Haar NM, de Roock S, Vastert SJ, Bogaert D. The human microbiome and juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2016;14(1):55. doi: 10.1186/s12969-016-0114-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Hales CM, Kit BK, Gu Q, Ogden CL. Trends in prescription medication use among children and adolescents-United States, 1999-2014. JAMA. 2018;319(19):2009–2020. doi: 10.1001/jama.2018.5690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Bhalodi AA, van Engelen TSR, Virk HS, Wiersinga WJ. Impact of antimicrobial therapy on the gut microbiome. J Antimicrob Chemother. 2019;74(Suppl 1):i6–i15. doi: 10.1093/jac/dky530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Francino MP. Antibiotics and the human gut microbiome: Dysbioses and accumulation of resistances. Front Microbiol. 2015;6:1543. doi: 10.3389/fmicb.2015.01543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.McDonnell L, Gilkes A, Ashworth M, Rowland V, Harries TH, Armstrong D, White P. Association between antibiotics and gut microbiome dysbiosis in children: systematic review and meta-analysis. Gut Microbes. 2021;13(1):1–18. doi: 10.1080/19490976.2020.1870402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Arvonen M, Virta LJ, Pokka T, Kroger L, Vahasalo P. Repeated exposure to antibiotics in infancy: a predisposing factor for juvenile idiopathic arthritis or a sign of this group's greater susceptibility to infections? J Rheumatol. 2015;42(3):521–526. doi: 10.3899/jrheum.140348. [DOI] [PubMed] [Google Scholar]
  • 24.Horton DB, Scott FI, Haynes K, Putt ME, Rose CD, Lewis JD, Strom BL. Antibiotic exposure and juvenile idiopathic arthritis: a case-control study. Pediatrics. 2015;136(2):e333–e343. doi: 10.1542/peds.2015-0036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Sultan AA, Mallen C, Muller S, Hider S, Scott I, Helliwell T, Hall LJ. Antibiotic use and the risk of rheumatoid arthritis: a population-based case-control study. BMC Med. 2019;17(1):154. doi: 10.1186/s12916-019-1394-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Carlens C, Jacobsson L, Brandt L, Cnattingius S, Stephansson O, Askling J. Perinatal characteristics, early life infections and later risk of rheumatoid arthritis and juvenile idiopathic arthritis. Ann Rheum Dis. 2009;68(7):1159–1164. doi: 10.1136/ard.2008.089342. [DOI] [PubMed] [Google Scholar]
  • 27.Ludvigsson J, Ludvigsson M, Sepa A. Screening for prediabetes in the general child population: maternal attitude to participation. Pediatr Diabetes. 2001;2(4):170–174. doi: 10.1034/j.1399-5448.2001.20405.x. [DOI] [PubMed] [Google Scholar]
  • 28.Nygren M, Carstensen J, Koch F, Ludvigsson J, Frostell A. Experience of a serious life event increases the risk for childhood type 1 diabetes: the ABIS population-based prospective cohort study. Diabetologia. 2015;58(6):1188–1197. doi: 10.1007/s00125-015-3555-2. [DOI] [PubMed] [Google Scholar]
  • 29.Lunde AS, Lundeborg S, Lettenstrom GS, Thygesen L, Huebner J. The person-number systems of Sweden, Norway, Denmark, and Israel. Vital Health Stat. 1980;2(84):1–59. [PubMed] [Google Scholar]
  • 30.Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138–2149. doi: 10.1016/S0140-6736(11)60244-4. [DOI] [PubMed] [Google Scholar]
  • 31.Gowdie PJ, Tse SM. Juvenile idiopathic arthritis. Pediatr Clin N Am. 2012;59(2):301–327. doi: 10.1016/j.pcl.2012.03.014. [DOI] [PubMed] [Google Scholar]
  • 32.Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*) Annu Rev Immunol. 2009;27(1):621–668. doi: 10.1146/annurev.immunol.25.022106.141627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Chong CYL, Vatanen T, Alexander T, Bloomfield FH, O'Sullivan JM. Factors associated with the microbiome in moderate-late preterm babies: a cohort study from the DIAMOND randomized controlled trial. Front Cell Infect Microbiol. 2021;11:595323. doi: 10.3389/fcimb.2021.595323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Dong YQ, Wang W, Li J, Ma MS, Zhong LQ, Wei QJ, Song HM. Characterization of microbiota in systemic-onset juvenile idiopathic arthritis with different disease severities. World J Clin Cases. 2019;7(18):2734–2745. doi: 10.12998/wjcc.v7.i18.2734. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Picco P, Gattorno M, Marchese N, Vignola S, Sormani MP, Barabino A, Buoncompagni A. Increased gut permeability in juvenile chronic arthritides. A multivariate analysis of the diagnostic parameters. Clin Exp Rheumatol. 2000;18(6):773–778. [PubMed] [Google Scholar]
  • 36.Manasson J, Blank RB, Scher JU. The microbiome in rheumatology: where are we and where should we go? Ann Rheum Dis. 2020;79(6):727–733. doi: 10.1136/annrheumdis-2019-216631. [DOI] [PubMed] [Google Scholar]
  • 37.Perez-Cobas AE, Gosalbes MJ, Friedrichs A, Knecht H, Artacho A, Eismann K, Otto W, Rojo D, Bargiela R, von Bergen M, et al. Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut. 2013;62(11):1591–1601. doi: 10.1136/gutjnl-2012-303184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Shamriz O, Mizrahi H, Werbner M, Shoenfeld Y, Avni O, Koren O. Microbiota at the crossroads of autoimmunity. Autoimmun Rev. 2016;15(9):859–869. doi: 10.1016/j.autrev.2016.07.012. [DOI] [PubMed] [Google Scholar]
  • 39.Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121–141. doi: 10.1016/j.cell.2014.03.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.De Luca F, Shoenfeld Y. The microbiome in autoimmune diseases. Clin Exp Immunol. 2019;195(1):74–85. doi: 10.1111/cei.13158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Kolho KL, Korpela K, Jaakkola T, Pichai MV, Zoetendal EG, Salonen A, de Vos WM. Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation. Am J Gastroenterol. 2015;110(6):921–930. doi: 10.1038/ajg.2015.149. [DOI] [PubMed] [Google Scholar]
  • 42.Giongo A, Gano KA, Crabb DB, Mukherjee N, Novelo LL, Casella G, Drew JC, Ilonen J, Knip M, Hyoty H, et al. Toward defining the autoimmune microbiome for type 1 diabetes. ISME J. 2011;5(1):82–91. doi: 10.1038/ismej.2010.92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Hevia A, Milani C, Lopez P, Cuervo A, Arboleya S, Duranti S, Turroni F, Gonzalez S, Suarez A, Gueimonde M, et al. Intestinal dysbiosis associated with systemic lupus erythematosus. mBio. 2014;5(5):e01548–e01514. doi: 10.1128/mBio.01548-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, Maertens M, Joos R. Gut inflammation in children with late onset pauciarticular juvenile chronic arthritis and evolution to adult spondyloarthropathy--a prospective study. J Rheumatol. 1993;20(9):1567–1572. [PubMed] [Google Scholar]
  • 45.Arvonen M, Vahasalo P, Turunen S, Salo HM, Maki M, Laurila K, Vaarala O, Karttunen TJ. Altered expression of intestinal human leucocyte antigen D-related and immune signalling molecules in juvenile idiopathic arthritis. Clin Exp Immunol. 2012;170(3):266–273. doi: 10.1111/j.1365-2249.2012.04663.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Conti F, Borrelli O, Anania C, Marocchi E, Romeo EF, Paganelli M, Valesini G, Cucchiara S. Chronic intestinal inflammation and seronegative spondyloarthropathy in children. Dig Liver Dis. 2005;37(10):761–767. doi: 10.1016/j.dld.2005.04.028. [DOI] [PubMed] [Google Scholar]
  • 47.Stoll ML, Kumar R, Morrow CD, Lefkowitz EJ, Cui X, Genin A, Cron RQ, Elson CO. Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis-related arthritis. Arthritis Res Ther. 2014;16(6):486. doi: 10.1186/s13075-014-0486-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Arvonen M, Vanni P, Sarangi AN, Tejesvi MV, Vahasalo P, Aggarwal A, Stoll ML. Microbial orchestra in juvenile idiopathic arthritis: sounds of disarray? Immunol Rev. 2020;294(1):9–26. doi: 10.1111/imr.12826. [DOI] [PubMed] [Google Scholar]
  • 49.Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. PLoS Biol. 2007;5(7):e177. doi: 10.1371/journal.pbio.0050177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, Magris M, Hidalgo G, Baldassano RN, Anokhin AP, Heath AC, Warner B, Reeder J, Kuczynski J, Caporaso JG, Lozupone CA, Lauber C, Clemente JC, Knights D, Knight R, Gordon JI. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222–227. doi: 10.1038/nature11053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Bokulich NA, Chung J, Battaglia T, Henderson N, Jay M, Li H, Lieber AD, Wu F, Perez-Perez GI, Chen Y, et al. Antibiotics, birth mode, and diet shape microbiome maturation during early life. Sci Transl Med. 2016;8(343):343ra382. doi: 10.1126/scitranslmed.aad7121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Penders J, Thijs C, Vink C, Stelma FF, Snijders B, Kummeling I, van den Brandt PA, Stobberingh EE. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics. 2006;118(2):511–521. doi: 10.1542/peds.2005-2824. [DOI] [PubMed] [Google Scholar]
  • 53.Stewardson AJ, Gaia N, Francois P, Malhotra-Kumar S, Delemont C, Martinez de Tejada B, Schrenzel J, Harbarth S, Lazarevic V, Saturn WP, et al. Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota. Clin Microbiol Infect. 2015;21(4):344 e341–344 e311. doi: 10.1016/j.cmi.2014.11.016. [DOI] [PubMed] [Google Scholar]
  • 54.Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A. 2011;108(Suppl 1):4554–4561. doi: 10.1073/pnas.1000087107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Jernberg C, Lofmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 2007;1(1):56–66. doi: 10.1038/ismej.2007.3. [DOI] [PubMed] [Google Scholar]
  • 56.Sepa A, Frodi A, Ludvigsson J. Psychosocial correlates of parenting stress, lack of support and lack of confidence/security. Scand J Psychol. 2004;45(2):169–179. doi: 10.1111/j.1467-9450.2004.00392.x. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The datasets are available from Johnny Ludvigsson, project leader of ABIS, on reasonable request.

Articles from Pediatric Rheumatology Online Journal are provided here courtesy of BMC

RESOURCES